Goldman Sachs Group Inc Puma Biotechnology, Inc. Transaction History

Goldman Sachs Group Inc

$780 Billion
Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 234,617 shares of PBYI stock, worth $1.16 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

234,617

Previous 202,029 16.13%

Holding current value

$1.16 Million

Previous $692,000 73.84%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$3.07 - $5.73 $100,045 - $186,729	32,588 Added 16.13%	234,617 $1.2 Million
Q2 2025 Aug 14, 2025	SELL	$2.74 - $3.72 $252,666 - $343,036	-92,214 Reduced 31.34%	202,029 $692,000
Q1 2025 May 09, 2025	SELL	$2.76 - $3.88 $54,797 - $77,033	-19,854 Reduced 6.32%	294,243 $870,000
Q4 2024 Feb 11, 2025	BUY	$2.42 - $3.39 $20,277 - $28,404	8,379 Added 2.74%	314,097 $957,000
Q3 2024 Nov 14, 2024	BUY	$2.25 - $4.03 $236,551 - $423,690	105,134 Added 52.41%	305,718 $779,000

Q2 2024 Aug 13, 2024	SELL	$2.92 - $5.83 $729,988 - $1.46 Million	-249,996 Reduced 55.48%	200,584 $653,000
Q1 2024 May 15, 2024	BUY	$4.29 - $7.4 $1.44 Million - $2.48 Million	334,625 Added 288.58%	450,580 $2.39 Million
Q4 2023 Feb 13, 2024	BUY	$2.23 - $4.49 $70,938 - $142,831	31,811 Added 37.81%	115,955 $502,000
Q3 2023 May 14, 2024	SELL	$2.63 - $4.09 $83,662 - $130,106	-31,811 Reduced 27.43%	84,144 $221,000
Q3 2023 Nov 14, 2023	BUY	$2.63 - $4.09 $26,904 - $41,840	10,230 Added 13.84%	84,144 $221,000
Q2 2023 May 14, 2024	SELL	$2.6 - $3.58 $234 - $322	-90 Reduced 0.12%	73,914 $260,000
Q2 2023 Aug 14, 2023	SELL	$2.6 - $3.58 $234 - $322	-90 Reduced 0.12%	73,914 $260,000
Q1 2023 May 14, 2024	SELL	$2.21 - $4.82 $5,407 - $11,794	-2,447 Reduced 3.2%	74,004 $228,000
Q1 2023 May 11, 2023	SELL	$2.21 - $4.82 $5,407 - $11,794	-2,447 Reduced 3.2%	74,004 $228,000
Q4 2022 May 14, 2024	SELL	$2.12 - $5.08 $91,331 - $218,851	-43,081 Reduced 36.04%	76,451 $323,000
Q4 2022 Feb 13, 2023	SELL	$2.12 - $5.08 $91,331 - $218,851	-43,081 Reduced 36.04%	76,451 $323,000
Q3 2022 May 14, 2024	SELL	$2.27 - $3.84 $230,087 - $389,222	-101,360 Reduced 45.89%	119,532 $284,000
Q3 2022 Nov 10, 2022	SELL	$2.27 - $3.84 $230,087 - $389,222	-101,360 Reduced 45.89%	119,532 $0
Q2 2022 May 14, 2024	BUY	$1.64 - $3.3 $172,096 - $346,292	104,937 Added 90.5%	220,892 $629,000
Q2 2022 Aug 15, 2022	SELL	$1.64 - $3.3 $359,064 - $722,508	-218,942 Reduced 49.78%	220,892 $629,000
Q1 2022 May 16, 2022	SELL	$2.13 - $3.24 $3.93 Million - $5.97 Million	-1,843,331 Reduced 80.74%	439,834 $1.27 Million
Q4 2021 Feb 14, 2022	BUY	$2.85 - $6.58 $4.2 Million - $9.71 Million	1,475,239 Added 182.6%	2,283,165 $6.94 Million
Q3 2021 Nov 10, 2021	BUY	$6.63 - $9.39 $5.36 Million - $7.59 Million	807,926 New	807,926 $5.66 Million

Others Institutions Holding PBYI

# of Institutions

135

Shares Held

35.2M

Call Options Held

264K

Put Options Held

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $226M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Puma Biotechnology, Inc. Transaction History